IsoPlexis to present data at SITC 2021

By The Science Advisory Board staff writers

November 5, 2021 -- IsoPlexis will present data from its IsoLight and IsoSpark platforms at the annual meeting of the Society for Immunotherapy of Cancer (SITC) on November 11 virtually and in person at the Walter E. Washington Convention Center in Washington, DC.

The company will reveal data outlining how to leverage certain proteomically active single cells and their genetic drivers identified simultaneously through single-cell transcriptomics and proteomics analyses on IsoPlexis' Duomic platform. The company said the data has implications for CAR T studies and other applications.

The presentation will take place on Thursday, November 11 from 12:15 to 1:15 p.m. EDT in meeting room 204ABC. Conference attendees can visit the IsoPlexis booth (No. 7) to see the platform. In-booth presentations will be given on Friday, November 12 and Saturday, November 13.

IsoPlexis raises $125M in IPO
IsoPlexis completed an initial public offering (IPO) on October 12, closing with $125 million on the sale of approximately 8.3 million shares...
IsoPlexis acquires sequencing methodology IP
IsoPlexis has acquired an intellectual property (IP) portfolio of 86 patents related to DNA and RNA sequencing, which it is integrating into its single-cell...
IsoPlexis launches new personalized lab systems
IsoPlexis has launched two new personalized lab systems, IsoSpark and IsoSpark Duo for high-throughput proteomics.
IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners...
IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter